Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $73.4 million.

  • Phathom Pharmaceuticals' Shares Outstanding (Diluted Average) rose 1356.78% to $73.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.4 million, marking a year-over-year increase of 1356.78%. This contributed to the annual value of $63.2 million for FY2024, which is 2317.67% up from last year.
  • Phathom Pharmaceuticals' Shares Outstanding (Diluted Average) amounted to $73.4 million in Q3 2025, which was up 1356.78% from $72.5 million recorded in Q2 2025.
  • Over the past 5 years, Phathom Pharmaceuticals' Shares Outstanding (Diluted Average) peaked at $73.4 million during Q3 2025, and registered a low of $38.0 million during Q1 2022.
  • For the 4-year period, Phathom Pharmaceuticals' Shares Outstanding (Diluted Average) averaged around $54.4 million, with its median value being $56.8 million (2023).
  • Within the past 5 years, the most significant YoY rise in Phathom Pharmaceuticals' Shares Outstanding (Diluted Average) was 4626.99% (2023), while the steepest drop was 1135.1% (2023).
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $39.1 million in 2022, then soared by 31.11% to $51.3 million in 2023, then increased by 23.18% to $63.2 million in 2024, then rose by 16.18% to $73.4 million in 2025.
  • Its last three reported values are $73.4 million in Q3 2025, $72.5 million for Q2 2025, and $72.0 million during Q1 2025.